Carregant...

Multiple choices for HIV therapy with integrase strand transfer inhibitors

Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Raffi, Francois, Wainberg, Mark A
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549750/
https://ncbi.nlm.nih.gov/pubmed/23253887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-9-110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!